Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia

• Status: Completed
• Trial end date: 2021-06-30
• Target enrollment: 0
• Participant gender: All

Summary

Randomized, prospective, controlled open label clinical trial aimed at investigating if the addition of inhaled corticosteroids (budesonide) reduces treatment failure (defined as a composite variable by the initiation of treatment with high flow-O2 therapy, non-invasive or invasive ventilation, systemic steroids, use of biologics (anti IL-6 or anti IL-1) and/or death) according to hospital standard of care guidance) at day 15 after initiation of therapeutic intervention.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sara Varea
• Treatments: Budesonide

Criteria

Inclusion Criteria:

• COVID19 positive

• hospitalized because of pneumonia (status #3 - #4 World Health Organization (WHO) scale)

• without contraindications to receive study treatment

• informed consent

Exclusion Criteria:

• receiving corticoids (inhaled or systemic)

• receiving anti Interleukin-1 (IL-1) or anti-IL-6 drugs

• receiving high flow oxygen therapy

• receiving mechanical ventilation

• pregnancy

• participating in another intervention trial for COVID19